# US 2016/0355661 A1 · Lyophilized Foams of End Block Containing Absorbable Polymers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355661 A1
- Document ID: US20160355661A1
- Status: Published application
- Kind: A1
- Application number: 14/728,226
- Filed: 2015-06-02
- Published: 2016-12-08
- Earliest claimed: 2015-06-02
- Assignees: Ethicon, Inc.
- Applicants: Ethicon, Inc.
- Inventors: Jackie Donners; Marc Wisnudel; Mark Timmer
- Web page: https://patentgrep.com/patent/US20160355661A1

## CPC

- C08J 9/26: by elimination of a solid phase from a macromolecular composition or article, e.g. leaching out
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/146: {Porous materials, e.g. foams or sponges}
- A61L 31/148: {Materials at least partially resorbable by the body}
- C08G 63/08: Lactones or lactides
- C08J 9/36: After-treatment (C08J9/22 takes precedence)
- C08J 2201/048: Elimination of a frozen liquid phase
- C08J 2201/0482: the liquid phase being organic
- C08J 2205/02: the finished foam itself being a gel or a gel being temporarily formed when processing the foamable composition
- C08J 2205/05: Open cells, i.e. more than 50% of the pores are open
- C08J 2207/10: Medical applications, e.g. biocompatible scaffolds
- C08J 2300/16: Biodegradable polymers
- C08J 2367/04: Polyesters derived from hydroxy carboxylic acids, e.g. lactones (C08J2367/06 takes precedence)
- C08J: WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H (working, e.g. shaping, of plastics B29)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS

## Abstract

Novel absorbable foams, lyophilizing solutions, and lyophilizing and annealing processes are disclosed. The foams are made from copolymers of glycolide and epsilon-caprolactone. The foams are useful in or as implantable medical devices.

## Claims

### Claim 1

An absorbable polymer foam, comprising:
a semicrystalline absorbable segmented copolymer having a random segment of repeating units of polymerized glycolide and polymerized epsilon-caprolactone and at least one segment that comprises predominantly polymerized glycolide, wherein the mole ratio of polymerized glycolide to polymerized epsilon-caprolactone of the entire segmented copolymer is between about 55:45 to about 65:35, and having a mole ratio of polymerized glycolide to polymerized epsilon-caprolactone in the random segment between about 45:55 to about 60:40.

### Claim 2 (depends on 1)

The absorbable foam of claim 1 wherein the copolymer has an inherent viscosity between about 0.5 dL/g and about 2.5 dl/g, as measured in a 0.1 g/dl solution of HFIP at 25° C.

### Claim 3 (depends on 1)

The foam of claim 1 in which the solids content is between about 3 weight percent to about 20 weight percent.

### Claim 4 (depends on 3)

The foam of claim 3 having a solid content between 5 weight percent and 15 weight percent.

### Claim 5 (depends on 1)

The foam of claim 1 having a thickness between about 0.5 mm to about 13 mm.

### Claim 6 (depends on 5)

The foam of claim 5 having a thickness between about 1 mm and about 5 mm.

### Claim 7 (depends on 1)

The foam of claim 1 having a compressive pressure at 2 mm height greater than 0.5 gf/mm2 after 28 days of incubation in a buffer of pH 7.27 at 37° C. under continuous compression.

### Claim 8 (depends on 7)

The foam of claim 7 prepared from 10 weight percent lyophilization solution.

### Claim 9 (depends on 1)

The foam of claim 1 prepared having a degradation coefficient less than −0.095 gf/(mm2·day) when incubated in a buffer of pH 7.27 at 37° C. under continuous compression.

### Claim 10 (depends on 9)

The foam of claim 9 prepared from 10 weight percent lyophilization solution.

### Claim 11 (depends on 1)

The foam of claim 1 having mechanical integrity at least 30 days post implantation.

### Claim 12 (depends on 1)

The foam of claim 1 having mechanical integrity at least 60 days post-implantation.

### Claim 13 (depends on 1)

The foam of claim 1 having a crystallinity level greater than about 10 percent.

### Claim 14 (depends on 1)

The foam of claim 1 having a crystallinity level greater than about 20 percent.

### Claim 15

A method of making an absorbable foam by a lyophilization process, comprising the steps of:
a) providing an absorbable polymer comprising a semicrystalline, absorbable, segmented copolymer having repeating units of polymerized glycolide and polymerized epsilon-caprolactone, wherein the mole ratio of polymerized glycolide to polymerized epsilon-caprolactone is about 55:45 to about 65:35, and having a mole ratio of polymerized glycolide to polymerized epsilon-caprolactone in the random segment between about 45:55 to about 60:40;
b) dissolving a sufficient quantity of the copolymer in a suitable solvent to form a lyophilizing solution;
c) pouring at least a part of the solution at a sufficiently effective temperature to prevent premature gel formation into a suitable mold;
d) freezing the solution at a fast enough rate to prevent premature gel formation in order to facilitate solvent removal in a subsequent lyophilization process; and,
e) subjecting the frozen solution in the mold to a lyophilizing process, wherein the pressure is lowered and heat is applied to sublimate the solvent and form an absorbable foam.

### Claim 16 (depends on 15)

The method of claim 15, wherein the copolymer has an inherent viscosity between about 0.5 dL/g and about 2.5 dl/g, as measured in a 0.1 g/dl solution of HFIP at 25° C.

### Claim 17 (depends on 15)

The method of claim 15, wherein the solvent is selected from the group consisting of 1,4-dioxane, a mixture of at least 90 weight percent 1,4-dioxane and no more than 10 weight percent water, and a mixture of at least 90 weight percent 1,4-dioxane and no more than 10 weight percent of an organic alcohol having a molecular weight of less than 1,500.

### Claim 18 (depends on 15)

The method of claim 15 wherein the solid content of the lyophilization solution is between about 3 and about 20 weight percent.

### Claim 19 (depends on 15)

The method of claim 15 wherein the solid content of the lyophilization solution is between about 5 and about 15 weight percent.

### Claim 20 (depends on 15)

The method of claim 15 wherein the lyophilization solution is poured at a temperature above 50° C. into a suitable mold.

### Claim 21 (depends on 15)

The method of claim 15, wherein the rate of freezing is equal to or faster than −5° C. per minute.

### Claim 22 (depends on 15)

The method of claim 15 wherein the rate of freezing is equal to or faster than −10° C. per minute.

### Claim 23

A lyophilizing solution, comprising:
a solvent selected from the group consisting of 1,4-dioxane, a mixture of at least 90 weight percent 1,4-dioxane and no more than 10 weight percent water, and a mixture of at least 90 weight percent 1,4-dioxane and no more than 10 weight percent of an organic alcohol having a molecular weight of less than 1,500 Daltons; and,
about 3 wt. % to about 20 wt. % of a semicrystalline, absorbable, segmented copolymer, having repeating units of polymerized glycolide and polymerized epsilon-caprolactone, wherein the mole ratio of polymerized glycolide to polymerized epsilon-caprolactone is between about 55:45 to about 65:35, and having a mole ratio of polymerized glycolide to polymerized epsilon-caprolactone in the random segment between about 45:55 to about 60:40.

### Claim 24 (depends on 23)

The solution of claim 23, wherein the copolymer has an inherent viscosity between about 0.5 dL/g and about 2.5 dl/g, as measured in a 0.1 g/dl solution of HFIP at 25° C.

### Claim 25 (depends on 23)

The solution of claim 23 wherein the solid content of the lyophilization solution is between about 3 and about 20 weight percent.

### Claim 26 (depends on 23)

The solution of claim 23 wherein the solid content of the lyophilization solution is between about 5 and about 15 weight percent.

### Claim 27 (depends on 23)

The solution of claim 23 wherein the solution is maintained at a temperature to prevent premature gel formation.

### Claim 28 (depends on 23)

The solution of claim 23 wherein the solution is maintained at a temperature above 50° C.

### Claim 29 (depends on 1)

A method of annealing the foam of claim 1, wherein the foam is heated to a temperature of about 60° C. to about 110° C. and maintained at the temperature for about 1 hour to about 12 hours.

### Claim 30 (depends on 29)

The method of claim 29, wherein the foam is heated to a temperature of about 70° C. to about 100° C.

### Claim 31 (depends on 30)

The method of claim 30, wherein the foam is heated to a temperature of about 85° C. to about 95° C.

### Claim 32 (depends on 29)

The method of claim 29 wherein the foam is heated for about 4 to about 8 hours.
